Please provide your email address to receive an email when new articles are posted on . The FDA approved label changes to the HIV drug Complera to include the treatment of HIV-1 infection in adult ...
complera The FDA has updated the label for Complera (emtricitabine, tenofovir disoproxil fumarate, rilpivirine; Gilead Sciences) tablets to include expanded use in pediatric patients aged 12 to less ...
Symptoms of HIV vary based on stage. In the first stage, those affected may experience symptoms like fever, chills, fatigue and mouth ulcers, although some individuals may not show any symptoms, which ...
Emtricitabine/rilpivirine/tenofovir DF FDC is indicated for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in antiretroviral treatment naïve ...
Drug combines emtricibatine with rilpivirine and tenofovir disoproxil fumarate. FDA approved Gilead Sciences’ Complera™ (emtricitabine/rilpivirine/tenofovir ...
As part of a strategy to switch patients to newer HIV treatments, Gilead Sciences late last week raised prices on a pair of older HIV medications that face patent expiration. This sort of maneuver is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback